AbbVie Inc.
ABBV- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001551152
In the last 90 days, AbbVie Inc. insiders filed 0 open-market purchases and 1 sale; 4,238 institutions reported holding it in 13F filings for Q2 2026, worth $335.4B in total; superinvestors Gardner Russo & Quinn and Harris Associates (Oakmark) hold it.
Holders of 5% or more of ABBV
Holders whose latest Schedule 13D or 13G filing reports 5% or more of AbbVie Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of AbbVie Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on AbbVie Inc., newest first.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 20251:20 PM ET | Vanguard Group Inc | 13G/A | 10.03%177.3M shares | – | Jun 30, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell AbbVie Inc. shares.
No Form 144 notices for AbbVie Inc. are on file.